THE PREVALENCE OF METABOLIC SYNDROME IN PATIENTS WITH POLYCYSTIC OVARY SYNDROME
AbstractBackground:The metabolic syndrome ( syndrome X ) , also called "insulin resistance syndrome" is a cluster of cardiovascular risk factors associated with excess fat. the metabolic syndrome is more common among women with PCOS than in normal women), particularly in those with hyperinsulinaemia and obesity Objective: The Aim of the study was to determine the prevalence of metabolic syndrome, and it’s main determinants in women with PCOS. Methods: Two –hundred twenty women , 105 patients with polycystic ovary syndrome ( PCOS) and 115 control , were included in this study to determine the prevalence of the metabolic syndrome & its main determinants among women with PCOS . Results: The study revealed that 82.1% of women with PCOS were nulliparae compared to 8.91% of controls ( P < 0.001) . Blood pressure > 130/ 85 mm.Hg and waist circumference > 88 cm were found among 37.14% and 60% of patients with PCOS respectively in comparison to 12.17% and 25.2% of control women respectively ( P <0.001). Over weight and obesity were observed among 48.6% and 40% of PCOS women respectively compared to 25.2% and 12.2% of controls respectively ( P < 0.001) . Only 3.3% of patients with PCOS were fertile , 73.9% with primary infertility and 22.8% with secondary infertility . The comparative figures among controls were 82.3% , 4.2% and 13.5% ( P < 0.001) . The main menstrual disorder associated with PCOS was oligomenorrhoea , observed in 72.4 of patients , compared to 3.5% in control women ( P < 0.001) . Hirsutism was found among 62.9% of PCOS patients in comparison to 5.2% of controls ( P < 0.001) . Women with PCOS showed significantly higher FBG , TC, TG and LDL-C levels ( P < 0.001) and significantly lower HDL-C levels ( P < 0.01) compared to control women . The frequency of metabolic syndrome in PCOS was 34.3% compared to 6.1% in conrol women ( P < 0.001) . Conclusion : the prevalence of metabolic syndrome in PCOS is nearly 6 times higher than in controls . Women with PCOS share multiple cardiovascular risk factors , and thereby , more prone to cardiovascular events .
Beata Banszewska , Antoni J, Robert Z, Leszek P : Lipids in polycystic ovary syndrome ; Role of hyperinsulinemia and effects of metformin ; American Journal of obstetric and Gynaecology. ( 2006); 194: PP 1266-72 .
Diamanti-Kandarakis E , Kouli CR, Filandraf A et al : A survey of the polycystic ovary syndrome in the Greek island of Lesbos ; hormonal and metabolic profile – J clin Endocrino Metab . 1999 ; 84(11) : PP 4006-11 .
Elting MW, Korsen TJ, Schoemaker J : Obesity , rather than menstrual cycle pattern or follicle cohort size , determines hyperinsulinaemia, dyslipidaemia and hypertension in ageing women with polycystic ovary syndrome . Clinical Endocrinology 2001;55(6): PP 767-76 .
Atiomo WV, Bates SA , condon JE. et al . The plasminogen activator system in women with polycystic ovary syndrome . Fertility sterility 1998; 69: PP 236-41 .
Conway GS, Agrawal R, Betteridge DJ, Jacobs HS . Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome . Clinical Endocrinology 1992; 37: PP 119-25.
Glueck CJ , Morrison JA, Friedman LA. et al. Obesity , free testosterone , and cardiovascular risk factors in adolescents with polycystic ovary syndrome and regularly cycling adolescents . Metabolism . 2006; 55: PP 508-14 .
Silva Rdo C, Pardini DP, Kater CE. Polycystic ovary syndrome, metabolic syndrome, cardiovascular risk and the role of insulin sensitizing agents . Arq Bras Endocrinol Metabol . 2006; 50(2) : PP 281-90 .
Sharma ST, Nestler JE. Prevention of diabetes and cardiovascular disease in women with PCOS : Treatment with insulin sensitizers. Endocrinology and Metablism . 2006; 20: PP 245-60 .
Dokras A, Bochner M , Hollinrake E, Markham S, et al . Screening women with polycystic ovary syndrome for metabolic syndrome . 2005; 106(1) : PP 131-7 .
Korhonen S, Hippelainen M, Niskanen L ; et al . Relationship of the metabolic syndrome and obesity to polycystic ovary syndrome : - a controlled , population – based study . Am . J Obstet Gynecol . 2001: 184( 3) : PP 289-96 .
Federman DD. Ovary. In : Dale DC, Federman DD, Web MD Sciemtific American Medicine, 2003 edn. New York , Web MD Inc : 2003: 641-654 .
Crowley WFJr, Hall JE, Martin KA, et al. An overview of the diagnostic consideration in polycystic ovary syndrome . Ann NY Acad Sci 1993; 687: 235 .
Hayes FJ , Taylor AE, Martin KA, et al. Use of a gonadotropin – releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome : assessment of neuroendocrine and androgen dynamics . J Clin Endocrinol Metab 1998; 83: 2343 .
Ehrmann DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion . Endocr Rev 1995; 16: 322 .
Azziz R, Black V, Hines GA, et al. Adrenal androgen excess in the poly cystic ovary syndrome: sensitivity and responsivity of the hypothalamic– pituitary – adrenal axis . J Clin Endocrinol Metab 1998; 83: 2317 .
Barbieri RL. Hyperandrogenism , insulin resistance and a canthosis nigricans : 10 years of progress . J Reprod Med 1994; 93: 327 .
Dunaif A. Insulin resistance and the polycystic ovary syndrome : mechanism and implications for pathogenesis . Endocr Rev 1997; 18: 774.
Kazer RR. The polycystic ovary. Semin Reprod Endocrinol 1997; 15 (3).
How lett TA. Endocrine disease . In : Kumar P, Clark M. Clinical Medicine , 6th edn. Edinburgh , Elsevier Saunders , 2005: 1035-1100 .
Glueck CJ, Papanna R, Wang P et al . Incidence and treatment of metabolic syndrome in newly referred women with confirmed polycystic ovarian syndrome . Metabolism . 2003; 52: PP 908-15 .
Ehrmann DA, Liljenquist DR, Kaszak et al . Prevalence and predictors of metabolic syndrome in women with polycystic ovary syndrome. J Clin. Endocrinology and Metabolism . 2006; 91: PP 48-53 .
Faloia E, Canibus P, Gattic , et al. Body composition , fat distribution and metabolic characteristics in lean and obese women with polycystic ovary syndrome . J Endocrinol Invest . 2004; 27( 5): PP 424-9.
Ricardo Azziz . How Prevalent is Metabolic Syndrome in Women With Polycystic Ovary Syndrome ? Nature clinical Practice Endocrinology and Metabolism. 2006; 2: PP 260-264 .
Barbieri RL. Polycystic ovary syndrome. In : Dale DC, Federman DD. Web MD Scientific American Medicine , 2003 edn, New York ; web MD Inc: 2003: 962-972 .
Sam S, Legro RS, Bentley-Lewis R, Dunsif A. Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome . J Clin . Endocrinology and Metabolism .
Rajkhowa M, Neary RH, Kumpatla P, et al. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome. J clin . Endocrinology and Metabolism . 1997; 82(10): PP 3389-94 .
Pirwany IR, Fleming R, Greer IA, et al . Lipids and lipoprotein subfractions in women with PCOS : relationship to metabolic and endocrine parameters . Clin . Endocrinol . 2001; 54(4): PP 447-53 .
Carmina E, Napoli N, Longo RA, et al . Metabolic syndrome in polycystic ovary syndrome . ( PCOS) : lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS . Eur J Endocrinol . 2006; 154(1): 141-5 .
Carmina E. Metabolic syndrome in polycystic ovary syndrome . Minerva Ginecol. 2006; 58(2): PP 109-14 .